"In a market that continues to value late-stage products and fiscally responsible pharma, spin-outs are a win-win solution, creating a biotech start-up with an experienced team and products in the clinic while allowing pharma to save on development costs with the potential for receiving revenue from future products. Panelists will explore the various types of spin-outs and what makes a spin-out successful for all parties involved."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.